Manitoba
Health and Seniors Care

Manitoba HIV Medication Program Drug List

Effective July 26, 2021

HIV Drug Classification (e.g. Nucleoside and Nucleotide Reverse Transcriptase Inhibitors)	DIN	Brand Name	Generic Name	Format	Strength	Listing Status	EDS Criteria (if applicable)
FIXED-DOSE COMBINATIONS	02416662	TEVA-ABACAVIR/LAMIVUDINE	ABACAVIR/LAMIVUDINE	TAB	600/300MG	PART 1	N/A
FIXED-DOSE COMBINATIONS	02454513	AURO-ABACAVIR/LAMIVUDINE	ABACAVIR/LAMIVUDINE	TAB	600/300MG	PART 1	N/A
FIXED-DOSE COMBINATIONS	02450682	MYLAN-ABACAVIR/LAMIVUDINE	ABACAVIR/LAMIVUDINE	TAB	600/300MG	PART 1	N/A
FIXED-DOSE COMBINATIONS	02458381	PMS-ABACAVIR/LAMVUDINE	ABACAVIR/LAMIVUDINE	TAB	600/300MG	PART 1	N/A
FIXED-DOSE COMBINATIONS	02399539	APO-ABACAVIR/LAMIVUDINE	ABACAVIR-LAMIVUDINE	TAB	600/300MG	PART 1	N/A
FIXED-DOSE COMBINATIONS	02478579	BIKTARVY	BICTEGRAVIR-EMTRICITABINE-TENOFOVIR AL	TAB	50/200/25MG	PART 3	For the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults with no known substitution associated with resistance to the individual components of BIKTARVY
FIXED-DOSE COMBINATIONS	02449498	GENVOYA	COBI/EMTRI/ELVIT/TENOFO ALAFE	TAB	150/150/200/10MG	PART 3	As a complete regimen for the treatment of HIV-1 infection in adult and pediatric patients 12 years of age and older (and weighing > 35kg) and with no known mutations associated with resistance to the individual components of Genvoya
FIXED-DOSE COMBINATIONS	02397137	STRIBILD	COBI/EMTRI/ELVIT/TENOFO DISOPR	TAB	150/150/200/300MG	PART 3	As a complete regimen for antiretroviral treatment naive HIV-1 infected patients in whom efavirenz is not indicated
FIXED-DOSE COMBINATIONS	02430932	TRIUMEQ	DOLUTEGRAVIR/ABACAVIR/LAMIVUDI	TAB	50/600/300	PART 3	For the treatment of HIV in both treatment-naive and treatment-experienced adults
FIXED-DOSE COMBINATIONS	02491753	DOVATO	DOLUTEGRAVIR/LAMIVUDINE	TAB	50/300MG	PART 3	As a complete regimen for the treatment of Human Immunodeficiency Virus – Type 1 (HIV-1) infection in adults and adolescents 12 years of age and older and weighting at least 40 kg, only if the following conditions are met: Initiation criteria: The patient must be naïve to any antiretroviral therapy (ART) and have an HIV-1 viral load ≤500.000 copies/ml
FIXED-DOSE COMBINATIONS	02475774	JULUCA	DOLUTEGRAVIR-RILPIVIRINE	TAB	50/25MG	PART 3	As a complete regimen to replace the current antiretroviral (cARV) regimen for the treatment of human immunodeficiency virus (HIV-1) infection in adults who are virologically stable and suppressed (HIV-1 RNA less than 50 copies per mL)
FIXED-DOSE COMBINATIONS	02482592	DELSTRIGO	DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOP	TAB	100/300/300MG	PART 3	Complete regimen for the treatment of HIV-1 infection in adults without past or present evidence of viral resistance to doravirine (DOR), lamivudine (3TC) or tenofovir
FIXED-DOSE COMBINATIONS	02393549	TEVA-EFAVIRE/EMTRICITA/TENOFO	EFAVIRENZ/EMTRICITABINE/TENOFO	TAB	6/2/3 X100	PART 3	For the treament of HIV-1 infection for patients where the virus is susceptible to each of efavirenz, emtricitabine, tenofovir
FIXED-DOSE COMBINATIONS	02487284	PMS-EFAVIR-EMTRIC-TENOFO	EFAVIRENZ/EMTRICITABINE/TENOFO	TAB	6/2/3X100	PART 3	For the treament of HIV-1 infection for patients where the virus is susceptible to each of efavirenz, emtricitabine, tenofovir
FIXED-DOSE COMBINATIONS	02484676	SANDOZ EFAVIR/EMTRIC/TENOFO	EFAVIRENZ/EMTRICITABINE/TENOFO	TAB	6/2/3X100	PART 3	For the treament of HIV-1 infection for patients where the virus is susceptible to each of efavirenz, emtricitabine, tenofovir
FIXED-DOSE COMBINATIONS	02461412	MYLAN-EFAVIRE/EMTRICITA/TENOFO	EFAVIRENZ/EMTRICITABINE/TENOFO	TAB	6/2/3X100	PART 3	For the treament of HIV-1 infection for patients where the virus is susceptible to each of efavirenz, emtricitabine, tenofovir
FIXED-DOSE COMBINATIONS	02478404	AURO-EFAVIR-EMTRIC-TENOFO	EFAVIRENZ/EMTRICITABINE/TENOFO	TAB	6/2/3X100	PART 3	For the treament of HIV-1 infection for patients where the virus is susceptible to each of efavirenz, emtricitabine, tenofovir

FIXED-DOSE COMBINATIONS	02468247	APO-EFAVIR-EMTRIC-TENOFO	EFAVIRENZ/EMTRICITABINE/TENOFO	TAB	6/2/3X100	PART 3	For the treament of HIV-1 infection for patients where the virus is susceptible to each of efavirenz, emtricitabine, tenofovir
FIXED-DOSE COMBINATIONS	02374129	COMPLERA	EMTRICITABINE/RILPIVIRINE/TENO	TAB	200/25/300	PART 3	For the treatment of human immunodeficiency virus type 1 (HIV-1) in antiretroviral treatment-naive patients, or to replace the three components given as dual or triple therapy for patients stabilized on appropriate doses.
FIXED-DOSE COMBINATIONS	02443902	MYLAN-EMTRICITABINE/TENOFOVIR	EMTRICITABINE/TENOFOVIR	TAB	200/300MG	PART 2	(a) For patients requiring post-exposure prophylaxis (PEP) to prevent infection subsequent to exposure to human blood andbody fluids that may transmit human immunodeficiency virus (HIV), up to a maximum of 28 days; (b) For the treatment as a dual nucleoside (nucleotide) option for treatment of HIV patients where the virus is susceptible to both these agents and efavirenz is not indicated due to adverse effects or antiretroviral resistance
FIXED-DOSE COMBINATIONS	02399059	TEVA-EMTRICITABINE/TENOFOVIR	EMTRICITABINE/TENOFOVIR	TAB	200/300MG	PART 2	(a) For patients requiring post-exposure prophylaxis (PEP) to prevent infection subsequent to exposure to human blood andbody fluids that may transmit human immunodeficiency virus (HIV), up to a maximum of 28 days; (b) For the treatment as a dual nucleoside (nucleotide) option for treatment of HIV patients where the virus is susceptible to both these agents and efavirenz is not indicated due to adverse effects or antiretroviral resistance
FIXED-DOSE COMBINATIONS	02452006	APO-EMTRICITABINE/TENOFOVIR	EMTRICITABINE/TENOFOVIR	TAB	200/300MG	PART 2	(a) For patients requiring post-exposure prophylaxis (PEP) to prevent infection subsequent to exposure to human blood andbody fluids that may transmit human immunodeficiency virus (HIV), up to a maximum of 28 days; (b) For the treatment as a dual nucleoside (nucleotide) option for treatment of HIV patients where the virus is susceptible to both these agents and efavirenz is not indicated due to adverse effects or antiretroviral resistance
FIXED-DOSE COMBINATIONS	02461110	PMS-EMTRICITABINE-TENOFOVIR	EMTRICITABINE/TENOFOVIR	TAB	200/300MG	PART 2	(a) For patients requiring post-exposure prophylaxis (PEP) to prevent infection subsequent to exposure to human blood andbody fluids that may transmit human immunodeficiency virus (HIV), up to a maximum of 28 days; (b) For the treatment as a dual nucleoside (nucleotide) option for treatment of HIV patients where the virus is susceptible to both these agents and efavirenz is not indicated due to adverse effects or antiretroviral resistance
FIXED-DOSE COMBINATIONS	02487012	JAMP EMTRICITABINE/TENOFOVIR	EMTRICTIABINE/TENOFOVIR	TAB	200/300MG	PART 2	(a) For patients requiring post-exposure prophylaxis (PEP) to prevent infection subsequent to exposure to human blood andbody fluids that may transmit human immunodeficiency virus (HIV), up to a maximum of 28 days; (b) For the treatment as a dual nucleoside (nucleotide) option for treatment of HIV patients where the virus is susceptible to both these agents and efavirenz is not indicated due to adverse effects or antiretroviral resistance
FIXED-DOSE COMBINATIONS	02414414	AURO-LAMIVUDINE/ZIDOVUDINE	LAMIVUDINE/ZIDOVUDINE	TAB	150/300MG	PART 1	N/A
FIXED-DOSE COMBINATIONS	02375540	APO-LAMIVUDINE/ZIDOVUDINE	LAMIVUDINE/ZIDOVUDINE	TAB	150/300MG	PART 1	N/A

FIXED-DOSE COMBINATIONS	02461463	ODEFSEY	RILPIVIRINE-EMTRICITABINE-TENOFOVIR-ALAI	TAB	200/25/25MG	PART 3	As a complete regimen for the treatment of adults infected with HIV-1 infection with no known mutations associated with resistance to the non-nucleoside reverse-transcriptase inhibitor (NNRTI) class, tenofovir or FTC, and with a viral load greater than or equal to 100,000 copies/ml
FIXED-DOSE COMBINATIONS	02496356	AG-EMTRICITABINE/TENOFOVIR	TENOFOVIR DISOPROXIL FUMARATE-EMTRICI	TAB	200/300MG	PART 2	(a) For patients requiring post-exposure prophylaxis (PEP) to prevent infection subsequent to exposure to human blood andbody fluids that may transmit human immunodeficiency virus (HIV), up to a maximum of 28 days; (b) For the treatment as a dual nucleoside (nucleotide) option for treatment of HIV patients where the virus is susceptible to both these agents and efavirenz is not indicated due to adverse effects or antiretroviral resistance
FUSION INHIBITOR	02299852	CELSENTRI	MARAVIROC	TAB	300MG	PART 3	(a) For patients who have CCR5 tropic viruses, and (b) who have documented resistance to at least one agent from each of the three major classes of antiretroviral agents (nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors)
FUSION INHIBITOR	02299844	CELSENTRI	MARAVIROC	TAB	150MG	PART 3	(a) For patients who have CCR5 tropic viruses, and (b) who have documented resistance to at least one agent from each of the three major classes of antiretroviral agents (nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors)
INTEGRASE STRAND TRANSFER INHIBITOR	02414945	TIVICAY	DOLUTEGRAVIR SODIUM	TAB	50MG	PART 3	For the treatment of HIV in both treatment-naive and treatment-experienced adults and children 12 years of age and older weighing at least 40kg, in combination with other anti-retrovirals
INTEGRASE STRAND TRANSFER INHIBITOR	02301881	ISENTRESS	RALTEGRAVIR	TAB	400MG	PART 2	(a) For patients requiring post-exposure prophylaxis (PEP) to prevent infection subsequent to exposure to human blood andbody fluids that may transmit human immunodeficiency virus (HIV), up to a maximum of 28 days; (b) For the treatment of HIV infection in patients who are antiviral experienced and have had virologic failure due to resistance to at least one agent from each of the three major antiviral classes
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR	02481545	PIFELTRO	DORAVIRINE	TAB	100MG	PART 3	In combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence or viral resistance to DOR
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR	02389762	TEVA-EFAVINREZ	EFAVINREZ	TAB	600MG	PART 1	N/A
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR	02418428	AURO-EFAVIRENZ	EFAVIRENZ	TAB	600MG	PART 1	N/A
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR	02381524	MYLAN-EFAVIRENZ	EFAVIRENZ	TAB	600MG	PART 1	N/A
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR	02239886	SUSTIVA	EFAVIRENZ	CAP	50MG	PART 1	N/A
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR	02239888	SUSTIVA	EFAVIRENZ	CAP	200MG	PART 1	N/A
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR	02458233	JAMP-EFAVIRENZ	EFAVIRENZ	TAB	600MG	PART 1	N/A
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR	02375931	INTELENCE	ETRAVIRINE	TAB	200MG	PART 3	For the treatment of HIV-1 infection in treatment-experienced patients who have failed prior antiretroviral therapy and have HIV-1 strains resistant to multiple antiretroviral agents including other NNRTI's

NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR	02306778	INTELENCE	ETRAVIRINE	TAB	100MG	PART 3	For the treatment of HIV-1 infection in treatment-experienced patients who have failed prior antiretroviral therapy and have HIV-1 strains resistant to multiple antiretroviral agents including other NNRTI's
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR	02370603	EDURANT	RILPIVIRINE	TAB	25MG	PART 3	For the treatment of HIV-1 infected treatment-naive patients
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR	02396769	APO-ABACAVIR	ABACAVIR	TAB	300MG	PART 1	N/A
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR	02480956	MINT-ABACAVIR	ABACAVIR	TAB	300MG	PART 1	N/A
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR	02240358	ZIAGEN	ABACAVIR SULFATE	O/L	20MG/ML	PART 1	N/A
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR	02369052	APO-LAMIVUDINE	LAMIVUDINE	TAB	150MG	PART 1	N/A
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR	02393239	APO-LAMIVUDINE HBV	LAMIVUDINE	TAB	100MG	PART 1	N/A
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR	02369060	APO-LAMIVUDINE	LAMIVUDINE	TAB	300MG	PART 1	N/A
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR	02192691	3TC	LAMIVUDINE	SOL	10MG/ML	PART 1	N/A
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR	02452634	MYLAN-TENOFOVIR	TENOFOVIR DISOPROXIL FUMARATE	TAB	300MG	PART 3	As an alternative treatment for adult HIV patients who have experienced adverse events or virologic failure with nucleoside reverse transcriptase inhibitors
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR	02403889	TEVA-TENOFOVIR	TENOFOVIR DISOPROXIL FUMARATE	TAB	300MG	PART 3	As an alternative treatment for adult HIV patients who have experienced adverse events or virologic failure with nucleoside reverse transcriptase inhibitors
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR	02460173	AURO-TENOFOVIR	TENOFOVIR DISOPROXIL FUMARATE	TAB	300MG	PART 3	As an alternative treatment for adult HIV patients who have experienced adverse events or virologic failure with nucleoside reverse transcriptase inhibitors
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR	02451980	APO-TENOFOVIR	TENOFOVIR DISOPROXIL FUMARATE	TAB	300MG	PART 3	As an alternative treatment for adult HIV patients who have experienced adverse events or virologic failure with nucleoside reverse transcriptase inhibitors
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR	02479087	JAMP-TENOFOVIR	TENOFOVIR DISOPROXIL FUMARATE	TAB	300MG	PART 3	As an alternative treatment for adult HIV patients who have experienced adverse events or virologic failure with nucleoside reverse transcriptase inhibitors
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR	02472511	NAT-TENOFOVIR	TENOFOVIR DISOPROXIL FUMARATE	TAB	300MG	PART 3	As an alternative treatment for adult HIV patients who have experienced adverse events or virologic failure with nucleoside reverse transcriptase inhibitors
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR	02453940	PMS-TENOFOVIR	TENOFOVIR DISOPROXIL FUMARATE	TAB	300MG	PART 3	As an alternative treatment for adult HIV patients who have experienced adverse events or virologic failure with nucleoside reverse transcriptase inhibitors
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR	01902644	RETROVIR	ZIDOVUDINE	INJ	10MG/ML	PART 1	N/A
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR	01902652	RETROVIR	ZIDOVUDINE	SYR	10MG/ML	PART 1	N/A
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITOR	01946323	APO-ZIDOVUDINE	ZIDOVUDINE	CAP	100MG	PART 1	N/A
PROTEASE INHIBITOR	02456893	MYLAN-ATAZANAVIR	ATAZANAVIR	CAP	300MG	PART 1	N/A
PROTEASE INHIBITOR	02456877	MYLAN-ATAZANAVIR	ATAZANAVIR	TAB	150MG	PART 1	N/A
PROTEASE INHIBITOR	02443791	TEVA-ATAZANAVIR	ATAZANAVIR	CAP	150MG	PART 1	N/A
PROTEASE INHIBITOR	02443813	TEVA-ATAZANAVIR	ATAZANAVIR	CAP	200MG	PART 1	N/A
PROTEASE INHIBITOR	02443821	TEVA-ATAZANAVIR	ATAZANAVIR	CAP	300MG	PART 1	N/A
PROTEASE INHIBITOR	02456885	MYLAN-ATAZANAVIR	ATAZANAVIR	TAB	200MG	PART 1	N/A
PROTEASE INHIBITOR	02338432	PREZISTA	DARUNAVIR	TAB	75MG	PART 1	N/A
PROTEASE INHIBITOR	02369753	PREZISTA	DARUNAVIR	TAB	150MG	PART 1	N/A
PROTEASE INHIBITOR	02487241	APO-DARUNAVIR	DARUNAVIR	TAB	600MG	PART 1	N/A
PROTEASE INHIBITOR	02486121	AURO-DARUNAVIR	DARUNAVIR	TAB	600MG	PART 1	N/A
PROTEASE INHIBITOR	02487268	APO-DARUNAVIR	DARUNAVIR	TAB	800MG	PART 1	N/A
PROTEASE INHIBITOR	02486148	AURO-DARUNAVIR	DARUNAVIR	TAB	800MG	PART 1	N/A

PROTEASE INHIBITOR	02426501	PREZCOBIX	DARUNAVIR/COBICISTAT	TAB	800/150MG	PART 3	For the treatment of human immunodeficiency virus (HIV) infection in treatment-naive and treatment-experienced patients without darunavir (DRV) resistance-associated mutations (RAMS)
PROTEASE INHIBITOR	02261545	TELZIR	FOSAMPRENAVIR	TAB	700MG	PART 1	N/A
PROTEASE INHIBITOR	02261545	TELZIR	FOSAMPRENAVIR CALCIUM	TAB	700MG	PART 1	N/A
PROTEASE INHIBITOR	02312301	KALETRA	LOPINAVIR/RITONAVIR	TAB	100/25MG	PART 1	N/A
PROTEASE INHIBITOR	02243644	KALETRA	LOPINAVIR/RITONAVIR	O/L	80MG/20MG	PART 1	N/A
PROTEASE INHIBITOR	02285533	KALETRA	LOPINAVIR/RITONAVIR	TAB	200/50MG	PART 1	N/A
PROTEASE INHIBITOR	02238618	VIRACEPT	NELFINAVIR	PWS	50MG/G	PART 1	N/A
PROTEASE INHIBITOR	02238617	VIRACEPT	NELFINAVIR	TAB	250MG	PART 1	N/A
PROTEASE INHIBITOR	02248761	VIRACEPT	NELFINAVIR	TAB	625MG	PART 1	N/A
PROTEASE INHIBITOR	02405776	PMS-NEVIRAPINE	NEVIRAPINE	TAB	200MG	PART 1	N/A
PROTEASE INHIBITOR	02387727	MYLAN-NEVIRAPINE	NEVIRAPINE	TAB	200MG	PART 1	N/A
PROTEASE INHIBITOR	02318601	AURO-NEVIRAPINE	NEVIRAPINE	TAB	200MG	PART 1	N/A
PROTEASE INHIBITOR	02357593	NORVIR	RITONAVIR	TAB	100MG	PART 1	N/A
PROTEASE INHIBITOR	02229145	NORVIR	RITONAVIR	O/L	80MG/ML	PART 1	N/A
PROTEASE INHIBITOR	02216965	INVIRASE	SAQUINAVIR	CAP	200MG	PART 1	N/A
PROTEASE INHIBITOR	02279320	INVIRASE	SAQUINAVIR	TAB	500 MG	PART 1	N/A